Our CEO and Co-Founder explains why RegenMed is at a key inflection point in disrupting the enormous market opportunities in healthcare data.
Early investors can receive up to 25% bonus shares.
Healthcare is at a tipping point: soaring costs, eroding trust, worsening outcomes. Physicians, patients and even AI systems don’t know what’s true — because unbiased, trustworthy and clinically meaningful data is unavailable.
Today’s healthcare data is ingested, “structured”, and “cleansed” by third parties. Often for their specific commercial purposes.
Most data is incoherent, incomplete, and stale. It lacks clinically relevance as well as correlated outcomes.
Data is inaccessible to those who most need it — physicians and their patients. It is expensive, and unverifiable.
RegenMed partners with physician groups in any specialty to generate unbiased, high-quality datasets which deliver clinical, scientific, and financial return on investment.
Trustworthy datasets supporting clinical decision-making, medical innovation, and patient education.
RegenMed transforms real-world clinical data into valuable insights — by giving physicians and patients ownership of the process. Our SaaS platform, Circles™, is live, secure, and used globally.
"During my many decades of medical practice, Circles would have been immensely helpful in supporting clinical decision-making, and collaborating with peers."
"A unicorn company requires large market opportunities, a disruptive product with competitive moats, and seasoned leadership. We are proud of what we have already built, and excited about where we are going."
The healthcare data market and RegenMed are both at inflection points. Physicians, patients, governments, researchers and AI all need better quality, lower cost data. Circles deliver it. Our model is working — high gross margin, global customers, growing recurring revenues, issued patents, strong channel partners. Wise investments are about timing. The timing is right for RegenMed, and the large markets it is addressing.
To learn more about what it takes to build a billion-dollar company, and why we believe RegenMed can be such a company, watch the two short videos below.
Bonus shares stack! If you invest $15,000 in the first 45 days, you’ll receive 20% + 5% = 25% more shares in total.
RegenMed gave us the evidence we needed — not just data points, but decision-grade insights.
Peter Everts, PhD, FRSM
Medical Researcher and Data Partner
The Circles platform is incredibly user-friendly, seamlessly automating patient data collection for our analysis.
Grant Pagdin, M.D. | Pagdin Health
RegenMed — natural partner with turnkey platforms and experience.
Imran Siddiqui, M.D. | ROSM
RegenMed is a valuable ally in our effort to collect reliable and objective medical data.
Dr. Tsoukas | IARMES
The testimonials presented are the opinions of the individuals providing them. They may not represent the experience of all clients or investors and are not a guarantee of future performance or success. No compensation was provided for these testimonials unless explicitly stated
Your investment is only processed if the minimum funding threshold is met.
Yes — federal regulations allow a cancellation window. Here’s how it works.
Early-stage investing is long-term. This is about owning a piece of the future — not a quick flip.